Activity Screening and Structure Modification of Trigonelline as New Anticancer Drug for Non Small Cell Lung Cancer Through In Silico

Kelvin F. Pratama; Muhammad Fauzi; Aliya Nur Hasanah

doi:10.24198/ijpst.v7i3.26765

Activity Screening and Structure Modification of Trigonelline as New Anticancer Drug for Non Small Cell Lung Cancer Through In Silico

Kelvin F. Pratama, Muhammad Fauzi, Aliya Nur Hasanah

Abstrak

The biggest case of death in 2018 is caused by lung cancer. Non-small cell lung cancer (NSCLC) is most common. One of the cause lung cancer is the over expression of EGFR. Erlotinib is the first line of anticancer for NSCLC with EGFR mutations. However, erlotinib can cause side effects such as liver damage therefore new safe anticancer is needed. Trigonelline is an alkaloid compound from coffee beans that had anticancer activity in pancreatic cancer cells by inhibiting Nrf2 in vitro and in vivo at concentrations of 0.1-1 µM. Development of cancer cells by Nrf2 is regulated by EGFR. In this study screening and modification of trigonelline structure was carried out to obtain compounds that have anticancer activity on NSCLC against EGFR computationally. The research procedures carried out are modification of ten trigonelline derived structures, the molecular docking and prediction of physicochemical profiles from trigonelline and its modification also their ADMET. Based on results, KF9 has the lowest free energy of binding which was -8,88 kcal/mol and binds to Met769 which has biological activity with receptor. KF9 has good physiochemical profile and absorption, distribution, also toxicity parameters. KF9 has potential to become a new anticancer drug for NSCLC.

Keywords: Coffee, Drug discovery and Drug development, Molecular structure modification, Nonsmall cell lung cancer, Trigonelline

Teks Lengkap:

PDF

Referensi

Kemenkes RI. Pedoman Nasional Pelayanan Kedokteran : Kanker Paru. Jakarta : Komite Penanggulangan Kanker Nasional; 2017.

Global Cancer Observatory. Precentages of new cancer cases and cancer deaths worldwide in 2018. [Diunduh pada 15 Maret 2020]. Tersedia dari: https://gco.iarc.fr/

Drugbank. Erlotinib Drug. [Diakses pada Tanggal 1 Maret 2020]. Tersedia dari: https://www.drugbank.ca/drugs/DB00530.

Gridelli C, De MF, Di MM, Cortinovis D, Cappuzzo F, Mok T. Gefitinib as first line treatment for patients with advanced nonsmall-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. Journal of Lung Cancer. 2012;71(3):249-57.

Becker AMD, Van WA, Smitt EF, Postmus PE. Side-Effects of Long-Term Administration of Erlotinib in Patients with Non-small Cell Lung Cancer. Anticancer Res. 2010;30(4):1301-10.

Cancer Research UK. Side Effects of Erlotinib (Tarceva). [Diakses pada 1 Maret 2020]. Tersedia dari : https://www.cancerresearchuk.org/about-cancer/cancer-in%20general/treatment/cancer-drugs/drugs/erlotinib/side-effects

Wink M. Modes of Action of Herbal Medicines and Plant Secondary Metabolites. Medicines. 2015;2(3)251-286.

Mohamadi N, Sharififar F, Pournamdari M, Ansari M. A Review on Biosynthesis, Analytical Techniques, and Pharmacological Activities of Trigonelline as a Plant Alkaloid. Journal of Dietary Supplements 2017;15(2):207–222.

Bicho NC, Leitao AE, Ramalho JC, Lidon. Identification of Chemical Clusters Discriminators of Roast Degree in Arabica and Robusta Coffee Beans. Eur J Food ResTechnol. 2011;(233): 303-311.

Arlt A, Sebens S, Krebs S, Geismann C, Grossmann M, Kruse ML, et al. Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity. Oncogene. 2013;32(40):4825-4835.

Huo L, Li CW, Huang TH, Lam YC, Xia W, Tu C, et al. Activation of Keap1/Nrf2 signaling pathway by nuclear epidermal growth factor receptor in cancer cells. Am J Transl Res. 2014;6(6):649–663.

Ibrahim HK, Khalil HS, Langdon SP, Moult PR, Bown JL. NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib. Oxidative Medicine and Cellular Longevity. 2017;(3):1-19.

Janzen, SO. Chemistry of Coffee. Germany : Cafea Gmb; 2010.

Muchtaridi, Yanuar A, Megantara S, Purnomo H. Kimia Medisinal : Dasar-Dasar Dalam Perancangan Obat. Jakarta : Prenadamedia Group; 2018.

Allen WJ, & Rizzo RC. Implementation of the Hungarian Algorithm to Account for Ligand Symmetry and Similarity in Structure-Based Design. J Chem Inf Model. 2014;(54):518–529.

Ismail RS, Ismail NS, Abuserii S, El EDAA. Recent advances in 4-aminoquinazoline based scaffold derivatives targeting EGFR kinases as anticancer agents. Future Journal of Pharmaceutical Sciences. 2016;2(1):9–19

Nasab RR, Mansourian M, Hassanzadeh F, Shahlaei M. Exploring the interaction between epidermal growth factor receptor tyrosine kinase and some of the synthesized inhibitors using combination of in-silico and in-vitro cytotoxicity methods. Res Pharm Sci. 2018;13(6):509–522.

Choowongkomon K, Sawatdichaikul O, Songtawee N, Limtrakul J. Receptor-Based Virtual Screening of EGFR Kinase Inhibitors from the NCI Diversity Database. Molecules. 2010;15(6):4041-4054

Sugunakala S, & Selvaraj S. Identification Of Potential Inhibitors Of Epidermal Growth Factor Receptor Tyrosine Kinase By Virtual Screening And Docking Studies. Int J Pharm Sci Res. 2017;8(3):1264-74

Lipinski CA. Lead and Drug-Like Compounds: The Rule-of-Five Revolution. Drug Discov Today Technol. 2004;1(4):337-341.

Benet LZ, Hosey CM, Ursu O, Oprea TI. BDDCS, the Rule of 5 and drugability. Advanced Drug Delivery Reviews. 2016;(101):89–98.

Cheng F, Li W, Liu G, Tang Y: In Silico ADMET Prediction: Recent Advances, Current Challenges and Future Trends. Current Topics in Medicinal Chemistry. 2013;13(11):1273-1289.

Yaznadian M, Glynn SL, Wright JL, Hawi. A: Correlating Partitioning and Caco-2 Cell Permeability of Structurally Diverse Small Molecular Weight Compounds. Pharmaceutical Research. 2013;15(9):1490 – 1494.

Walmsley RM, & Billinton N. How accurate is in vitro prediction of carcinogenicity?. British Journal of Pharmacology. 2011;162(6):1250–1258.

Nohmi T, Masumura K, Toyoda-Hokaiwado, N. Transgenic rat models for mutagenesis and carcinogenesis. Genes and Enviroment. 2017;39(11).

DOI: https://doi.org/10.24198/ijpst.v7i3.26765